Discover the Future of CNS Therapeutics: The Promise of KCC2 Activation Join us on November 13 as we explore a breakthrough in neuroscience, focusing on a critical target in the central nervous system (CNS) – KCC2. This unique transporter, found exclusively in the brain, plays a fundamental role in controlling neuron excitability. Activating KCC2 holds transformative potential for treating a wide spectrum of neurological conditions by addressing the underlying mechanisms that drive disorders such as epilepsy, psychosis, and mood disorders. Ovid Therapeutics is at the forefront of advancing this field. We are proud to have developed multiple KCC2 activators and are on track to submit our first IND for OV350, a promising candidate that could open doors to life-changing therapies for those affected by CNS diseases. I’ll be joined by esteemed experts, Professors Stephen Moss, Jeffrey Noebels, and Karl Kieburtz, along with key leaders from Ovid, to discuss the groundbreaking science behind KCC2 activation. Together, we’ll delve into how this new approach could reshape treatment paradigms for brain disorders. Don’t miss this chance to engage with a new frontier in small molecule neurotherapeutics and witness the potential impact of KCC2 on the future of brain health. Save the Date: November 13 Be part of the conversation that could redefine the future of CNS treatments. Register to join in person: https://lnkd.in/dvZvmvCc Register to join the virtual webcast: https://lnkd.in/dWJfKxkV
We’re honored to welcome three recognized thought leaders in neurology and neuropharmacology to present at Ovid’s KCC2 Download Day next week. Stephen Moss, Jeff Noebels and Karl Kieburtz will discuss the biological functions, underlying mechanisms and therapeutic promise of directly activating KCC2. KCC2 is one of the most exciting novel pathways in neurology due to its role in modulating neuronal hyperexcitability and neuroinflammation, the root cause of many brain disorders. Join us on November 13 to explore the biological and therapeutic significance of KCC2 activation across a wide range of CNS conditions. Register to join in person: https://lnkd.in/eGzQqw9X Register to join the virtual webcast: https://lnkd.in/eCBq8gFC